Is There A Role For Surgery In Men With Nodal Oligometastatic Prostate Cancer After A Biochemical Failure?
Recently there have been a number of conversations in the prostate media around the topic of treating oligometastatic prostate cancer with a curative goal. Oligometastatic prostate cancer describes the disease state where primary treatment has [...]
Enzalutamide (XTANDI) Now Approved in Europe for Men With Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-Naïve
On Dec 2, 2014 Astellas Pharma Europe Ltd announced that the European Commission (EC) has granted a variation that amends their marketing authorization for enzalutamide (Xtandi). Based on this amended authorization Xtandi is now approved [...]
Disrupting Cancer – A Remarkable Sounding Researcher/Clinician – Dr. Pat Soon-Shing
On December 7, 2014 the TV show 60 Minutes (CBS) aired a very interesting story (narrated by Dr. Sanjay Gupta) interview about an amazing sounding man, Dr. Patrick Soon-Shing. To describe him as a genius [...]
Efficacy of Intermittent ADT with Degarelix, the New Gonadotrophin Releasing Hormone (GnRH) Antagonist
There has been much conversation surrounding the use of intermittent androgen deprivation (IAD) as opposed to continuous androgen deprivation (CAD) in men with prostate cancer who need hormone therapy (ADT). The question that has been [...]
Degarelix Monotherapy vs. Luteinizing Hormone-Releasing Hormone Agonists Plus Antiandrogen Flare Protection For Men With Advanced Prostate Cancer *
There are a number of different flavors of hormone therapy (ADT) used to treat advanced prostate cancer. However, they could be summed up and put into two different categories. 1- The use of luteinizing hormone-releasing [...]
Dealing with A New Health Issue – A Rare Cancer Along with Prostate Cancer
My wife Wendy wrote a post to the advanced prostate cancer online support group where she discussed our recent experience re-entering the healthcare system to deal with a non-prostate cancer issue. In the post she [...]